# Shanghai Henlius Biotech clinical trials: 133 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 133 trials with Shanghai Henlius Biotech as lead sponsor, 47 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shanghai Henlius Biotech: 133 rows for $6.65, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 133
- Recruiting or not yet: 47
- Read on: November 19, 2026

## Trials

The 25 newest of 133, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944690 | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | Advanced/Metastatic Solid Tumors | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944690) |
| November 13, 2026 | NCT07935941 | A Phase I Study of HLX109 in Healthy Participants | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | First in Man Study to Evaluate Initial Safety | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07935941) |
| October 8, 2026 | NCT07865910 | A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With... | Shanghai Henlius Biotech | Phase 2/3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 1,438 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865910) |
| September 17, 2026 | NCT07824869 | A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer... | Shanghai Henlius Biotech | Phase 2 | Not yet recruiting | HER2 + Breast Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824869) |
| August 20, 2026 | NCT07776132 | Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11 | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | Health Adult Subjects | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776132) |
| May 22, 2026 | NCT07601620 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early... | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | HER2 + Breast Cancer | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601620) |
| April 21, 2026 | NCT07543471 | A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | mCRC | 387 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543471) |
| April 21, 2026 | NCT07541534 | A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors | Shanghai Henlius Biotech | Phase 1 | Recruiting | Advanced/Metastatic Solid Tumors | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541534) |
| April 16, 2026 | NCT07533708 | A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours | Shanghai Henlius Biotech | Phase 1 | Recruiting | mCRPC or Advanced/Metastatic Solid Tumors | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533708) |
| April 8, 2026 | NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | Shanghai Henlius Biotech | Phase 1 | Recruiting | Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC) | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518043) |
| March 27, 2026 | NCT07495930 | Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo® | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | Health Adult Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07495930) |
| March 23, 2026 | NCT07487519 | Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or... | Shanghai Henlius Biotech | Phase 2 | Not yet recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07487519) |
| March 20, 2026 | NCT07484893 | A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | Healthy Adult Male | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07484893) |
| March 18, 2026 | NCT07480681 | Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in... | Shanghai Henlius Biotech | Phase 1 | Not yet recruiting | Advanced/Metastatic Solid Tumors | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480681) |
| March 17, 2026 | NCT07477587 | A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With... | Shanghai Henlius Biotech | Phase 1 | Recruiting | Multiple Myeloma (MM) | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477587) |
| March 16, 2026 | NCT07473726 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors | Shanghai Henlius Biotech | Phase 1 | Recruiting | Advanced/Metastatic Solid Tumors | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473726) |
| March 10, 2026 | NCT07459751 | A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus... | Shanghai Henlius Biotech | Phase 2/3 | Recruiting | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | 706 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459751) |
| March 10, 2026 | NCT07459738 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or... | Shanghai Henlius Biotech | Phase 2 | Not yet recruiting | Hormone Receptor Positive HER-2 Negative Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459738) |
| February 18, 2026 | NCT07416695 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC | Shanghai Henlius Biotech | Phase 1 | Recruiting | SCLC, NEC | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416695) |
| January 22, 2026 | NCT07358585 | A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer | Shanghai Henlius Biotech | Phase 1/2 | Not yet recruiting | Colon Cancer Adenocarcinoma | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358585) |
| January 6, 2026 | NCT07318883 | A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With... | Shanghai Henlius Biotech | Phase 2/3 | Not yet recruiting | Squamous NSCLC | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318883) |
| December 24, 2025 | NCT07301229 | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer | Shanghai Henlius Biotech | Phase 2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301229) |
| December 19, 2025 | NCT07294534 | A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant... | Shanghai Henlius Biotech | Phase 2/3 | Not yet recruiting | HER2 + Breast Cancer | 817 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294534) |
| December 19, 2025 | NCT07294508 | A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer | Shanghai Henlius Biotech | Phase 2/3 | Recruiting | HER2 + Breast Cancer | 706 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294508) |
| December 10, 2025 | NCT07274813 | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors | Shanghai Henlius Biotech | Early phase 1 | Recruiting | Advanced/Metastatic Solid Tumors, NSCLC | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07274813) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 48 |
| Phase 1/2 | 10 |
| Phase 2 | 43 |
| Phase 2/3 | 7 |
| Phase 3 | 23 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 42 |
| Completed | 28 |
| Recruiting | 27 |
| Not yet recruiting | 20 |
| Active not recruiting | 8 |
| Withdrawn | 5 |
| Terminated | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Breast Neoplasms | 8 |
| Carcinoma, Hepatocellular | 6 |
| Lymphoma | 4 |
| Stomach Neoplasms | 4 |
| COVID-19 | 4 |
| Colorectal Neoplasms | 4 |
| Small Cell Lung Carcinoma | 4 |
| Neoplasm Metastasis | 3 |
| Lymphoma, B-Cell | 3 |
| Macular Degeneration | 3 |
| Uterine Cervical Neoplasms | 3 |
| Triple Negative Breast Neoplasms | 2 |
| Melanoma | 2 |
| Multiple Myeloma | 2 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Diabetes Mellitus, Insulin-Dependent, 12 | 1 |
| Carcinoma, Renal Cell | 1 |
| Glomerulonephritis, Membranous | 1 |
| Lupus Nephritis | 1 |
| Carcinoma, Transitional Cell | 1 |
| Brain Neoplasms | 1 |
| Carcinoma | 1 |
| Histiocytosis, Langerhans-Cell | 1 |
| Erdheim-Chester Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B power plants and power plant companies in the United States](https://specstream.ai/data/businesses/b2b-power-plants-and-power-plant-companies/united-states)
- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [Masonry contractors in the United States](https://specstream.ai/data/businesses/masonry-contractors/united-states)
- [Sign makers in the United States](https://specstream.ai/data/businesses/sign-makers/united-states)
- [B2B international trade companies in the United States](https://specstream.ai/data/businesses/b2b-international-trade-companies/united-states)
- [Emergency and urgent care facilities in the United States](https://specstream.ai/data/businesses/emergency-and-urgent-care-facilities/united-states)
